Terumo Corp. (OTCMKTS:TRUMY) Short Interest Update

Key Points

• Terumo’s short interest fell sharply by 46% in July to 46,134 shares, representing just 0.0% of shares outstanding and a short-interest ratio of 0.2 days.
• The stock traded at $16.43, down 1.4%, while remaining well above its 50-day and 200-day moving averages. Terumo reported quarterly EPS of $0.30 and revenue of $1.97 billion, exceeding analyst expectations.
• Nomura upgraded Terumo from “Hold” to “Strong Buy,” contributing to a current analyst consensus rating of “Buy.”

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totaling 46,134 shares, a decline of 46.0% from the July 15th total of 85,412 shares. Based on an average daily trading volume, of 251,156 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the company's shares are sold short.

Terumo Stock Down 1.4%

Shares of OTCMKTS:TRUMY traded down $0.23 during trading on Monday, hitting $16.43. 26,048 shares of the company's stock traded hands, compared to its average volume of 279,280. The company has a current ratio of 1.59, a quick ratio of 0.97 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average price of $14.21 and a 200-day moving average price of $13.65. Terumo has a 52 week low of $12.08 and a 52 week high of $19.60. The company has a market cap of $24.24 billion, a price-to-earnings ratio of 23.15 and a beta of 0.68.

Terumo (OTCMKTS:TRUMY - Get Free Report) last posted its earnings results on Friday, August 7th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.13. The business had revenue of $1.97 billion during the quarter, compared to analysts' expectations of $1.84 billion. Terumo had a return on equity of 10.55% and a net margin of 13.83%. As a group, research analysts forecast that Terumo will post 0.7 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Nomura raised Terumo from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy".

Terumo Company Profile

Terumo Corporation OTCMKTS: TRUMY is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source